ML364
$350.00
CAS No.: 1991986-30-1
Catalog No.: 193709
Purity: 95%
MF: C24H18F3N3O3S2
MW: 517.554
Storage: 2-8 degree Celsius
SMILES: CC1=CC=C(C=C1)S(=O)(=O)NC1=C(C(=O)NC=2SC=C(N2)C2=CC=CC=C2)C=CC(=C1)C(F)(F)F
Catalog No.: 193709
Purity: 95%
MF: C24H18F3N3O3S2
MW: 517.554
Storage: 2-8 degree Celsius
SMILES: CC1=CC=C(C=C1)S(=O)(=O)NC1=C(C(=O)NC=2SC=C(N2)C2=CC=CC=C2)C=CC(=C1)C(F)(F)F
ML364; 2-(4-methylphenylsulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide; CAS No.: 1991986-30-1; ML364. PROPERTIES: ML364 is a white to off-white powder with the molecular formula C21H18F3N5O3. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety precautions include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 447.39 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms and aromatic rings that enhance binding affinity and metabolic resistance. Its logP value around 2.7 indicates a balance between hydrophilic and lipophilic characteristics. APPLICATIONS: ML364 functions as a selective inhibitor of the epidermal growth factor receptor (EGFR), investigated for the treatment of non-small cell lung cancer and other EGFR-driven malignancies. In preclinical research, it is used to study resistance mechanisms in EGFR-mutant cancers and to develop combination therapies that enhance treatment efficacy. The compound is employed in pharmacokinetic studies to evaluate drug metabolism and distribution patterns. Additionally, it serves as a research tool in signaling pathway analysis to understand EGFR-driven oncogenic processes. According to "Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy," ML364 represents a new generation of EGFR inhibitors designed to overcome acquired resistance in cancer treatment.
Reviews
Write Your Own Review